Acetylcholine-binding protein engineered to mimic the α4- α 4 binding pocket in α 4β2 nicotinic acetylcholine receptors reveals interface specific interactions important for binding and activity

Molecular Pharmacology

Volumn 88, Issue 4, 2015, Pages 697-707

  Shahsavar, Azadeh ^a   Ahring, Philip K ^b,c   Olsen, Jeppe A ^a,b,d   Krintel, Christian ^b   Kastrup, Jette S ^a   Balle, Thomas ^b   Gajhede, Michael ^a  

^a UNIVERSITY OF COPENHAGEN   (Denmark)

^b UNIVERSITY OF SYDNEY   (Australia)

^c Saniona A S   (Denmark)

^d NEUROSEARCH A S   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

1 (5 ETHOXYPYRIDIN 3 YL) 1,4 DIAZEPANE; 1 (6 BROMOPYRIDIN 3 YL) 1,4 DIAZEPANE; ACETYLCHOLINE BINDING PROTEIN; BINDING PROTEIN; HISTIDINE; NICOTINIC AGENT; NICOTINIC RECEPTOR ALPHA4BETA2; UNCLASSIFIED DRUG; ACHBP PROTEIN, LYMNAEA; CARRIER PROTEIN; NICOTINIC RECEPTOR; PROTEIN BINDING;

ARTICLE; BINDING AFFINITY; CONCENTRATION RESPONSE; CONTROLLED STUDY; CRYSTALLIZATION; DRUG BINDING SITE; DRUG EFFICACY; DRUG POTENCY; DRUG RECEPTOR BINDING; DRUG STRUCTURE; EC50; HYDROGEN BOND; IC50; LIGAND BINDING; LYMNAEA STAGNALIS; NONHUMAN; POINT MUTATION; PRIORITY JOURNAL; PROTEIN ENGINEERING; PROTEIN STRUCTURE; STOICHIOMETRY; STRUCTURE ACTIVITY RELATION; ANIMAL; BINDING SITE; CHEMISTRY; DOSE RESPONSE; FEMALE; HUMAN; INSECT; METABOLISM; MOLECULAR MIMICRY; PHYSIOLOGY; PROCEDURES; PROTEIN SECONDARY STRUCTURE; X RAY CRYSTALLOGRAPHY; XENOPUS LAEVIS;

ANIMALS; BINDING SITES; CARRIER PROTEINS; CRYSTALLOGRAPHY, X-RAY; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HUMANS; INSECTS; MOLECULAR MIMICRY; PROTEIN BINDING; PROTEIN ENGINEERING; PROTEIN STRUCTURE, SECONDARY; RECEPTORS, NICOTINIC; XENOPUS LAEVIS;

EID: 84946731556     PISSN: 0026895X     EISSN: 15210111     Source Type: Journal    
DOI: 10.1124/mol.115.098061     Document Type: Article

References (46)

1. Afonine PV, Grosse-Kunstleve RW, Echols N, Headd JJ, Moriarty NW, Mustyakimov M, Terwilliger TC, Urzhumtsev A, Zwart PH, and Adams PD (2012) Towards automated crystallographic structure refinement with phenix.refine. Acta Crystallogr D Biol Crystallogr 68:352-367.
2. Ahring PK, Olsen JA, Nielsen EØ, Peters D, Pedersen MHF, Rohde LA, Kastrup JS, Shahsavar A, Indurthi DC, and Chebib M et al. (2015) Engineered a4b2 nicotinic acetylcholine receptors as models for measuring agonist binding and effect at the orthosteric low-affinity a4-a4 interface. Neuropharmacology 92:135-145.
3. Althoff T, Hibbs RE, Banerjee S, and Gouaux E (2014) X-ray structures of GluCl in apo states reveal a gating mechanism of Cys-loop receptors. Nature 512:333-337.
4. Audouze K, Nielsen EØ, Olsen GM, Ahring P, Jørgensen TD, Peters D, Liljefors T, and Balle T (2006) New ligands with affinity for the a4b2 subtype of nicotinic acetylcholine receptors. Synthesis, receptor binding, and 3D-QSAR modeling. J Med Chem 49:3159-3171.
5. Bocquet N, Nury H, Baaden M, Le Poupon C, Changeux J-P, Delarue M, and Corringer P-J (2009) X-ray structure of a pentameric ligand-gated ion channel in an apparently open conformation. Nature 457:111-114.
6. Brejc K, van Dijk WJ, Klaassen RV, Schuurmans M, van Der Oost J, Smit AB, and Sixma TK (2001) Crystal structure of an ACh-binding protein reveals the ligand-binding domain of nicotinic receptors. Nature 411:269-276.
7. Carbone AL, Moroni M, Groot-Kormelink PJ, and Bermudez I (2009) Pentameric concatenated (a4)(2)(b2)(3) and (a4)(3)(b2)(2) nicotinic acetylcholine receptors: subunit arrangement determines functional expression. Br J Pharmacol 156: 970-981.
8. Celie PHN, Kasheverov IE, Mordvintsev DY, Hogg RC, van Nierop P, van Elk R, van Rossum-Fikkert SE, Zhmak MN, Bertrand D, and Tsetlin V et al. (2005) Crystal structure of nicotinic acetylcholine receptor homolog AChBP in complex with an alpha-conotoxin PnIA variant. Nat Struct Mol Biol 12:582-588.
9. Celie PHN, van Rossum-Fikkert SE, van Dijk WJ, Brejc K, Smit AB, and Sixma TK (2004) Nicotine and carbamylcholine binding to nicotinic acetylcholine receptors as studied in AChBP crystal structures. Neuron 41:907-914.
10. Chen VB, Arendall WB 3rd, Headd JJ, Keedy DA, Immormino RM, Kapral GJ, Murray LW, Richardson JS, and Richardson DC (2010) MolProbity: all-atom structure validation for macromolecular crystallography. Acta Crystallogr D Biol Crystallogr 66:12-21.
11. Emsley P and Cowtan K (2004) Coot: model-building tools for molecular graphics. Acta Crystallogr D Biol Crystallogr 60:2126-2132.
12. Emsley P, Lohkamp B, Scott WG, and Cowtan K (2010) Features and development of Coot. Acta Crystallogr D Biol Crystallogr 66:486-501.
13. Hansen SB, Sulzenbacher G, Huxford T, Marchot P, Taylor P, and Bourne Y (2005) Structures of Aplysia AChBP complexes with nicotinic agonists and antagonists reveal distinctive binding interfaces and conformations. EMBO J 24:3635-3646.
14. Harpsøe K, Ahring PK, Christensen JK, Jensen ML, Peters D, and Balle T (2011) Unraveling the high- And low-sensitivity agonist responses of nicotinic acetylcholine receptors. J Neurosci 31:10759-10766.
15. Harpsøe K, Hald H, Timmermann DB, Jensen ML, Dyhring T, Nielsen EØ, Peters D, Balle T, Gajhede M, and Kastrup JS et al. (2013) Molecular determinants of subtype-selective efficacies of cytisine and the novel compound NS3861 at heteromeric nicotinic acetylcholine receptors. J Biol Chem 288:2559-2570.
16. Hassaine G, Deluz C, Grasso L, Wyss R, Tol MB, Hovius R, Graff A, Stahlberg H, Tomizaki T, and Desmyter A et al. (2014) X-ray structure of the mouse serotonin 5-HT3 receptor. Nature 512:276-281.
17. Hibbs RE and Gouaux E (2011) Principles of activation and permeation in an anionselective Cys-loop receptor. Nature 474:54-60.
18. Hilf RJ and Dutzler R (2008) X-ray structure of a prokaryotic pentameric ligandgated ion channel. Nature 452:375-379.
19. Hilf RJ and Dutzler R (2009) Structure of a potentially open state of a protonactivated pentameric ligand-gated ion channel. Nature 457:115-118.
20. Ho SN, Hunt HD, Horton RM, Pullen JK, and Pease LR (1989) Site-directed mutagenesis by overlap extension using the polymerase chain reaction. Gene 77:51-59.
21. Jensen AA, Frølund B, Liljefors T, and Krogsgaard-Larsen P (2005) Neuronal nicotinic acetylcholine receptors: structural revelations, target identifications, and therapeutic inspirations. J Med Chem 48:4705-4745.
22. Kabsch W (2010) XDS. Acta Crystallogr D Biol Crystallogr 66:125-132.
23. Kuryatov A, Luo J, Cooper J, and Lindstrom J (2005) Nicotine acts as a pharmacological chaperone to up-regulate human a4b2 acetylcholine receptors. Mol Pharmacol 68:1839-1851.
24. Leslie AGW (1992) Recent changes to the MOSFLM package for processing and image plate data. Joint CCP4 1 ESF-EAMCB Newsletter on Protein Crystallography 26:29-35. http://www.ccp4.ac.uk/newsletters/No26.pdf.
25. Li S-X, Huang S, Bren N, Noridomi K, Dellisanti CD, Sine SM, and Chen L (2011) Ligand-binding domain of an a7-nicotinic receptor chimera and its complex with agonist. Nat Neurosci 14:1253-1259.
26. Marotta CB, Rreza I, Lester HA, and Dougherty DA (2014) Selective ligand behaviors provide new insights into agonist activation of nicotinic acetylcholine receptors. ACS Chem Biol 9:1153-1159.
27. Mazzaferro S, Gasparri F, New K, Alcaino C, Faundez M, Iturriaga Vasquez P, Vijayan R, Biggin PC, and Bermudez I (2014) Non-equivalent ligand selectivity of agonist sites in (a4b2)2a4 nicotinic acetylcholine receptors: a key determinant of agonist efficacy. J Biol Chem 289:21795-21806.
28. McCoy AJ, Grosse-Kunstleve RW, Adams PD, Winn MD, Storoni LC, and Read RJ (2007) Phaser crystallographic software. J Appl Cryst 40:658-674.
29. Miller PS and Aricescu AR (2014) Crystal structure of a human GABAA receptor. Nature 512:270-275.
30. Mirza NR, Larsen JS, Mathiasen C, Jacobsen TA, Munro G, Erichsen HK, Nielsen AN, Troelsen KB, Nielsen EØ, and Ahring PK (2008) NS11394 [39-[5- (1-hydroxy-1-methyl-ethyl)-benzoimidazol-1-yl]-biphenyl-2-carbonitrile], a unique subtype-selective GABAA receptor positive allosteric modulator: in vitro actions, pharmacokinetic properties and in vivo anxiolytic efficacy. J Pharmacol Exp Ther 327:954-968.
31. Moroni M, Vijayan R, Carbone A, Zwart R, Biggin PC, and Bermudez I (2008) Nonagonist- binding subunit interfaces confer distinct functional signatures to the alternate stoichiometries of the a4b2 nicotinic receptor: an a4-a4 interface is required for Zn21 potentiation. J Neurosci 28:6884-6894.
32. Moroni M, Zwart R, Sher E, Cassels BK, and Bermudez I (2006) a4b2 Nicotinic receptors with high and low acetylcholine sensitivity: pharmacology, stoichiometry, and sensitivity to long-term exposure to nicotine. Mol Pharmacol 70:755-768.
33. Nelson ME, Kuryatov A, Choi CH, Zhou Y, and Lindstrom J (2003) Alternate stoichiometries of a4b2 nicotinic acetylcholine receptors. Mol Pharmacol 63:332-341.
34. Nemecz A and Taylor P (2011) Creating an a7 nicotinic acetylcholine recognition domain from the acetylcholine-binding protein: crystallographic and ligand selectivity analyses. J Biol Chem 286:42555-42565.
35. Olsen JA, Ahring PK, Kastrup JS, Gajhede M, and Balle T (2014) Structural and functional studies of the modulator NS9283 reveal agonist-like mechanism of action at a4b2 nicotinic acetylcholine receptors. J Biol Chem 289:24911-24921.
36. Olsen JA, Balle T, Gajhede M, Ahring PK, and Kastrup JS (2014) Molecular recognition of the neurotransmitter acetylcholine by an acetylcholine binding protein reveals determinants of binding to nicotinic acetylcholine receptors. PLoS One 9: e91232.
37. Peters D, Olsen G, Nielsen EØ, and Nielsen SF (1999) inventors, NeuroSearch A/S, assignee. Heteroaryl diazabicycloalkanes as cholinergic ligands at nicotinic acetylcholine receptors. WIPO patent WO9921834. 1999 May 6.
38. Rohde LA, Ahring PK, Jensen ML, Nielsen EØ, Peters D, Helgstrand C, Krintel C, Harpsøe K, Gajhede M, and Kastrup JS et al. (2012) Intersubunit bridge formation governs agonist efficacy at nicotinic acetylcholine a4b2 receptors: unique role of halogen bonding revealed. J Biol Chem 287:4248-4259.
39. Sauguet L, Shahsavar A, Poitevin F, Huon C, Menny A, Nemecz À, Haouz A, Changeux J-P, Corringer P-J, and Delarue M (2014) Crystal structures of a pentameric ligand-gated ion channel provide a mechanism for activation. Proc Natl Acad Sci USA 111:966-971.
40. Shahsavar A, Kastrup JS, Nielsen EØ, Kristensen JL, Gajhede M, and Balle T (2012) Crystal structure of Lymnaea stagnalis AChBP complexed with the potent nAChR antagonist DHbE suggests a unique mode of antagonism. PLoS One 7:e40757.
41. Taly A, Corringer P-J, Guedin D, Lestage P, and Changeux J-P (2009) Nicotinic receptors: allosteric transitions and therapeutic targets in the nervous system. Nat Rev Drug Discov 8:733-750.
42. Tapia L, Kuryatov A, and Lindstrom J (2007) Ca21 permeability of the (a4)3(b2)2 stoichiometry greatly exceeds that of (a4)2(b2)3 human acetylcholine receptors. Mol Pharmacol 71:769-776.
43. Timmermann DB, Grønlien JH, Kohlhaas KL, Nielsen EØ, Dam E, Jørgensen TD, Ahring PK, Peters D, Holst D, and Christensen JK et al. (2007) An allosteric modulator of the a7 nicotinic acetylcholine receptor possessing cognition-enhancing properties in vivo. J Pharmacol Exp Ther 323:294-307.
44. Ussing CA, Hansen CP, Petersen JG, Jensen AA, Rohde LA, Ahring PK, Nielsen EØ, Kastrup JS, Gajhede M, and Frølund B et al. (2013) Synthesis, pharmacology, and biostructural characterization of novel a4b2 nicotinic acetylcholine receptor agonists. J Med Chem 56:940-951.
45. Xiao Y, Fan H, Musachio JL, Wei ZL, Chellappan SK, Kozikowski AP, and Kellar KJ (2006) Sazetidine-A, a novel ligand that desensitizes a4b2 nicotinic acetylcholine receptors without activating them. Mol Pharmacol 70:1454-1460.
46. Zwart R, Carbone AL, Moroni M, Bermudez I, Mogg AJ, Folly EA, Broad LM, Williams AC, Zhang D, and Ding C et al. (2008) Sazetidine-A is a potent and selective agonist at native and recombinant alpha 4 beta 2 nicotinic acetylcholine receptors. Mol Pharmacol 73:1838-1843.